PriceTargets.com logo

Graybug Vision - GRAY Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.59 As of 04/23/2024 01:00 AM ET
▲ +0.08 (1.77%)

This chart shows the closing price for GRAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Graybug Vision Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRAY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Graybug Vision in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.59.

This chart shows the closing price for GRAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Graybug Vision. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2022Piper SandlerLower TargetNeutral$56.00 ➝ $28.00Low
5/11/2022Cantor FitzgeraldLower Target$56.00 ➝ $35.00Medium
3/31/2022WedbushReiterated RatingNeutral$42.00Low
3/25/2022Cantor FitzgeraldReiterated RatingBuy$56.00Low
3/17/2022Cantor FitzgeraldLower TargetOverweight$84.00 ➝ $56.00High
1/3/2022Wells Fargo & CompanyInitiated CoverageOverweightLow
12/15/2021WedbushReiterated RatingNeutralMedium
5/19/2021Needham & Company LLCReiterated RatingBuy ➝ HoldLow
5/18/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$322.00 ➝ $70.00Low
5/13/2021Cantor FitzgeraldLower TargetOverweight$196.00 ➝ $84.00High
5/13/2021Needham & Company LLCDowngradeBuy ➝ HoldHigh
5/12/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$322.00 ➝ $70.00High
5/12/2021Piper SandlerLower TargetNeutral$140.00 ➝ $56.00High
3/15/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$378.00 ➝ $140.00N/A
3/15/2021WedbushReiterated RatingOutperform ➝ Neutral$574.00 ➝ $112.00N/A
3/9/2021WedbushDowngradeOutperform ➝ Neutral$574.00 ➝ $112.00Medium
3/9/2021SVB LeerinkLower TargetOutperform$630.00 ➝ $322.00High
3/9/2021Piper SandlerDowngradeOverweight ➝ Neutral$378.00 ➝ $140.00High
12/21/2020Cantor FitzgeraldInitiated CoverageOverweight$588.00High
10/20/2020OppenheimerInitiated CoverageOutperform$574.00Low
10/20/2020Robert W. BairdInitiated CoverageOverweight$378.00High
10/20/2020SVB LeerinkInitiated CoverageOutperform$490.00High
10/20/2020WedbushInitiated CoverageOutperform$574.00High
10/20/2020Piper SandlerInitiated CoverageOverweight$378.00High
10/20/2020Needham & Company LLCInitiated CoverageBuy$420.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Graybug Vision logo
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Read More

Today's Range

Now: $4.59
Low: $4.07
High: $4.59

50 Day Range

MA: $4.30
Low: $3.46
High: $5.23

52 Week Range

Now: $4.59
Low: $5.00
High: $22.12

Volume

19,657 shs

Average Volume

2,165 shs

Market Capitalization

$7.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Graybug Vision?

The following Wall Street sell-side analysts have issued research reports on Graybug Vision in the last twelve months:
View the latest analyst ratings for GRAY.

What is the current price target for Graybug Vision?

0 Wall Street analysts have set twelve-month price targets for Graybug Vision in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Graybug Vision in the next year.
View the latest price targets for GRAY.

What is the current consensus analyst rating for Graybug Vision?

Graybug Vision currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GRAY.

What other companies compete with Graybug Vision?

Other companies that are similar to Graybug Vision include eFFECTOR Therapeutics, Can-Fite BioPharma, Trevena, Clever Leaves and Kineta. Learn More about companies similar to Graybug Vision.

How do I contact Graybug Vision's investor relations team?

The official website for Graybug Vision is www.graybug.com. Learn More about contacing Graybug Vision investor relations.